GlassScriptPhysician profile
Jonathan Nattiv
NPI 1134516453
$3,105.11
in general payments reported to CMS, 2019-2025
9 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $254 · 2022: $422 · 2023: $578 · 2024: $544 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,469.20 | 2022-2025 | Impella |
| Abbott Laboratories | $1,009.71 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Impulse Dynamics (USA) INC. | $290.74 | 2022-2023 | Optimizer |
| Boston Scientific Corporation | $164.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.69 | 2022-2024 | |
| Scpharmaceuticals INC. | $34.91 | 2023 | |
| Amgen INC. | $27.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.59 | 2025 | Lifevest |
| Servier Pharmaceuticals LLC | $22.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Nattiv listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.